Featured
-
-
Research Highlight |
Artificially transplanted mitochondria in endothelial cells promote mitophagy
A study in Nature describes a single-cell-type strategy for vascular cell therapies that involves the artificial transplantation of mitochondria to endothelial cells, which promotes mitophagy and facilitates the formation of functional vessels in ischaemic tissue without the need for mesenchymal stromal cell support.
- Karina Huynh
-
-
-
Review Article |
Targeted delivery of therapeutic agents to the heart
For therapeutic materials to be delivered to the heart, several barriers need to be overcome. In this Review, Ishikawa and colleagues discuss strategies for targeted delivery of therapeutic materials to the heart, including the use of adeno-associated viruses and exosomes, with a focus on agents directed at modifying gene expression.
- Susmita Sahoo
- , Taro Kariya
- & Kiyotake Ishikawa
-
Research Highlight |
Exosome-derived microRNAs improve cardiac function
A new study identifies microRNAs that are enriched in exosomes secreted from cardiosphere-derived cells and which are associated with cardiac repair in pigs and humans with dilated cardiomyopathy.
- Andrew Robson
-
Research Highlight |
An acellular artificial cardiac patch for myocardial repair
An ‘off-the-shelf’, cell-free, artificial cardiac patch has been created that is easy to store and improves outcomes in rat and pig models of myocardial infarction.
- Gregory B. Lim
-
Research Highlight |
Stem cell therapy improves heart function by triggering an acute immune response
Stem cell therapy does not promote the regeneration or production of new cardiomyocytes in the injured heart but induces a wound healing response that contributes to improved cardiac function.
- Karina Huynh
-
Research Highlight |
Placental stem cells can regenerate the heart
Placental stem cells expressing caudal-type homeobox 2 can differentiate into cardiomyocytes and vascular cells, improving cardiac function in the infarcted hearts of mice.
- Karina Huynh
-
-
News & Views |
Exercising engineered heart muscle to maturity
The immaturity of stem cell-derived cardiomyocytes has impeded their use for in vitro disease modelling, cardiotoxicity assays, and cell-replacement therapy. Ronaldson-Bouchard and colleagues report unparalleled in vitro maturation of stem cell-derived cardiomyocytes. This advance promises to unlock the translational potential of these cells.
- Donghui Zhang
- & William T. Pu
-
-
Review Article |
Next-generation pacemakers: from small devices to biological pacemakers
Conduction system disorders lead to slow heart rates that are insufficient to support the circulation, necessitating implantation of electronic pacemakers. Current pacemakers, although effective, have limitations including lead malfunction, lack of autonomic responsiveness, and device-related infections. In this Review, Marbán and colleagues discuss next-generation electronic devices designed to address current limitations, as well as biological pacemakers as alternatives to implantable hardware.
- Eugenio Cingolani
- , Joshua I. Goldhaber
- & Eduardo Marbán
-
News & Views |
Cell therapy for cardiac repair: what is needed to move forward?
The ESC has updated its 2006 consensus statement on clinical investigation of autologous adult stem cells for the treatment of acute myocardial infarction and heart failure. This initiative by a group of leaders in the field stimulates much-needed reflection and provides guidance to make cell therapy a clinical reality. Here, we offer our own perspective.
- Roberto Bolli
- & Shahab Ghafghazi
-
-
-
-
Review Article |
Genome editing in cardiovascular diseases
Genome editing is being rapidly adopted into all fields of biomedical research, including the cardiovascular field. In this Review, Strong and Musunuru discuss the applications of genome-editing technology, including zinc finger nucleases, TALENs, and CRISPR/Cas9 systems, throughout cardiovascular disease research, their current limitations, and the prospect ofin vivogenome-editing therapies in the future.
- Alanna Strong
- & Kiran Musunuru
-
Reply |
Alternative approaches to generating cardiomyocytes are under development
- Ian Y. Chen
- , Elena Matsa
- & Joseph C. Wu
-
Correspondence |
Expandable progenitors from induced pluripotent stem cells
- Shigeo Masuda
- , Shigeru Miyagawa
- & Yoshiki Sawa
-
-
Review Article |
Induced pluripotent stem cells: at the heart of cardiovascular precision medicine
Human induced pluripotent stem cells (hiPSCs) can be differentiated into many cardiovascular cell types, including cardiomyocytes and endothelial cells. hiPSC-derived cardiovascular cells can recapitulate patient-specific and disease-specific phenotypes. In this Review, Chen et al. discuss how hiPSCs can be used as a platform for cardiovascular drug development and disease modelling, and can facilitate individualized therapy in the era of precision medicine.
- Ian Y. Chen
- , Elena Matsa
- & Joseph C. Wu
-
Research Highlight |
Mesenchymal stromal cell therapy improves myocardial function after severe ischaemic heart failure
- João H. Duarte
-
-
Correspondence |
Stem cells for cardiac repair—should we be cautious?
- Yu-Li Huang
- , Hong-Feng Tang
- & Yun-Zhao Hu
-
Reply |
Translation of regenerative technologies into clinical paradigms
- Atta Behfar
- , Ruben Crespo-Diaz
- & Bernard J. Gersh
-
Correspondence |
Emerging innovation towards safety in the clinical application of ESCs and iPSCs
- Shigeo Masuda
- , Shigeru Miyagawa
- & Yoshiki Sawa
-
Review Article |
Cell therapy for cardiac repair—lessons from clinical trials
The use of multipotent stem cells to achieve regeneration in cardiovascular disease has been the subject of continuous evaluation over the past decade. Dr Behfar and colleagues review experience obtained from trials of 'first-generation' cell-based therapy, and discuss the advances that have enabled the development of 'next-generation' stem-cell-based therapies targeting cardiovascular disease.
- Atta Behfar
- , Ruben Crespo-Diaz
- & Bernard J. Gersh
-
-
-
-
News & Views |
Bone-marrow-derived cells and heart failure—the debate goes on
The therapeutic efficacy of bone-marrow-derived cells in patients with acute or chronic myocardial infarction has been a matter of intense debate. Three new clinical trials—the Swiss-AMI, CELLWAVE, and C-CURE studies—unfortunately do not resolve the controversy in the field of cell therapy for the damaged heart.
- Annarosa Leri
- & Piero Anversa
-
-
Research Highlight |
Myocardial regeneration after infarction—promising phase I trial results
- Gregory B. Lim
-
-
A distinct platelet differentiation pathway is involved in age-related thrombocytosis
Stem-cell therapy restores heart function after MI in macaques
Exosome-based therapy to repair the injured heart
Allogenic mesenchymal stem cells for dilated cardiomyopathy
A step closer to cardiac repair therapies
Cell therapy improves outcomes in heart failure
BMMC treatment safe but not an improvement on standard therapy
Injection during CABG surgery helps failing hearts